http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Nanoscale piezoresponse studies of ferroelectric domains in epitaxial BiFeO3 nanostructures
Hong, Seungbum,Klug, Jeffrey A.,Park, Moonkyu,Imre, Alexandra,Bedzyk, Michael J.,No, Kwangsoo,Petford-Long, Amanda,Auciello, Orlando American Institute of Physics 2009 JOURNAL OF APPLIED PHYSICS - Vol.105 No.6
Measurements of Inelastic Neutron Scattering at 96 MeV from Carbon, Iron, Yttriumand Lead
A. Ohrn,C. Gustavsson,M. Blann,V. Blideanu,J. Blomgren,S. Chiba,H. Duarte,F. Haddad,C. Kalbach,J. Klug,A. Koning,C. Le brun,C. Lebrun,F. -R. Lecolley,X. Ledoux,N. Marie-noury,P. Mermod,L. Nilsson,M. O 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.23
Inelastic neutron scattering for ^(12)C, ^(56)Fe, ^(89)Y and ^(208)Pb have been measured at 96 MeV at the The Svedberg Laboratory in Uppsala and double-differential cross sections are reported. Data cover an excitation energy range of 0-45 MeV and the angular intervals are 28 - 58˚ for ^(12)C, 26 - 65˚ for ^(56)Fe and 26 - 52˚ for ^(89)Y and ^(208)Pb. In this experiment, neutron detection is based on conversion to protons in an active scintillator converter. An analysis technique in which the neutron spectra have been obtained through a folding procedure using the response of the detector system has been used. The results are compared to and are in reasonable agreement with several model predictions and with inelastic neutron scattering data at 65 MeV from University of California, Davis, USA.
Affinity chromatography and capillary electrophoresis for analysis of the yeast ribosomal proteins
( Miriam S. Goyder ),( Keith R. Willison ),( David R. Klug ),( Andrew J. Demello ),( Oscar Ces ) 생화학분자생물학회 (구 한국생화학분자생물학회) 2012 BMB Reports Vol.45 No.4
We present a top down separation platform for yeast ribosomal proteins using affinity chromatography and capillary electrophoresis which is designed to allow deposition of proteins onto a substrate. FLAG tagged ribosomes were affinity purified, and rRNA acid precipitation was performed on the ribosomes followed by capillary electrophoresis to separate the ribosomal proteins. Over 26 peaks were detected with excellent reproducibility ( 0.5% RSD migration time). This is the first reported separation of eukaryotic ribosomal proteins using capillary electrophoresis. The two stages in this workflow, affinity chromatography and capillary electrophoresis, share the advantages that they are fast, flexible and have small sample requirements in comparison to more commonly used techniques. This method is a remarkably quick route from cell to separation that has the potential to be coupled to high throughput readout platforms for studies of the ribosomal proteome. [BMB reports 2012; 45(4): 233-238]
Kochhar, Sonali,Excler, Jean-Louis,Bok, Karin,Gurwith, Marc,McNeil, Michael M.,Seligman, Stephen J.,Khuri-Bulos, Najwa,Klug, Bettina,Laderoute, Marian,Robertson, James S.,Singh, Vidisha,Chen, Robert T Elsevier Ltd. 2019 Vaccine Vol. No.
<P><B>Abstract</B></P> <P>Live viral vectors that express heterologous antigens of the target pathogen are being investigated in the development of novel vaccines against serious infectious agents like HIV and Ebola. As some live recombinant vectored vaccines may be replication-competent, a key challenge is defining the length of time for monitoring potential adverse events following immunization (AEFI) in clinical trials and epidemiologic studies. This time period must be chosen with care and based on considerations of pre-clinical and clinical trials data, biological plausibility and practical feasibility. The available options include: (1) adapting from the current relevant regulatory guidelines; (2) convening a panel of experts to review the evidence from a systematic literature search to narrow down a list of likely <I>potential or known</I> AEFI and establish the optimal risk window(s); and (3) conducting “near real-time“ prospective monitoring for <I>unknown</I> clustering’s of AEFI in validated large linked vaccine safety databases using Rapid Cycle Analysis for pre-specified adverse events of special interest (AESI) and Treescan to identify previously unsuspected outcomes. The risk window established by any of these options could be used along with (4) establishing a registry of clinically validated pre-specified AESI to include in case-control studies. Depending on the infrastructure, human resources and databases available in different countries, the appropriate option or combination of options can be determined by regulatory agencies and investigators.</P>